SGTX News and Press, Sigilon Therapeutics Inc. From 04/16/21

The following slide deck was published by Sigilon Therapeutics, Inc. in conjunction with this event. For further details see: Sigilon Therapeutics (SGTX) Presents At 20th Annual Virtual Healthcare Conference - Slideshow

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executiv...

The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire CAMBRIDGE, Mass. , March 30, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the pot...

Sigilon Therapeutics (SGTX): Q4 GAAP EPS of -$1.15 misses by $0.59.Revenue of $3.76M (+21.7% Y/Y) beats by $0.56M.Press Release For further details see: Sigilon Therapeutics EPS misses by $0.59, beats on revenue

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quart...

The FDA has granted Orphan Drug Designation to Sigilon Therapeutics' (SGTX) SIG-007 for the treatment of Fabry disease, a progressive, lysosomal disease.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.Sigilon ha...

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and ...

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executiv...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire CAMBRIDGE, Mass. , Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life science...